secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-08-13T20:10:53+00:00
Accession:  0001437749-26-027672
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Q2 revenue $37.6M (+99% YoY), raises FY26 guidance to >$145M
-----------------------------------------------------------------

- Q2 net revenue $37.6M vs $18.9M YoY; GAAP EPS $0.35, non-GAAP $0.43.
- Adjusted EBITDA $16.2M (43% margin) vs $3.1M (16%) YoY; EBITDA $14.1M.
- FY26 revenue guidance raised to >$145M (from >$120M); Adjusted EBITDA margin ≥35% (from ≥30%).
- HEMANGEOL relaunch May 1; ~95% patient conversion by end of June; ASN-001 licensed.
- Acquired U.S. rights to IMPAVIDO (launch Sept 2026); KHINDIVI PAS submitted for expanded indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/0001437749-26-027672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/eton20260608_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer